Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSITION-20: Osimertinib in EGFR exon 20–mutant, non-T790M NSCLC
2017-004734-28Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Primary endpoint: Best overall response (BOR) by RECIST 1.1. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-004734-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004734-28.